Literature DB >> 7248157

Enhancement of the effect of cytotoxic drugs by radiosensitizers.

W M Martin, N J McNally, J De Ronde.   

Abstract

Misonidazole (MISO) potentiates the action of cyclophosphamide (CY) and melphalan in the WHFIB culture-adapted fibrosarcoma, whether assayed by cell survival or tumour-growth delay. In the case of CY, MISO also inhibited recovery from potentially lethal drug damage. The optimum effect was seen when MISO was given 1 h before CY, though it was also effective when given 6 h before or 1 h after the drug. Other radiosensitizers also potentiated the action of CY. There was only a small effect of MISO on the LD50 of CY and no effect on CY toxicity as assayed by changes in blood counts or damage to bladder epithelium. However, mice bearing multiple lung tumours were less able to cope with the combined treatment than those bearing s.c. tumours.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248157      PMCID: PMC2010716          DOI: 10.1038/bjc.1981.113

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Hypoxic sensitizers: radiobiological studies at the cellular level.

Authors:  E J Hall; L Roizin-Towle
Journal:  Radiology       Date:  1975-11       Impact factor: 11.105

2.  Selective chemotherapy of noncycling cells in an in vitro tumor model.

Authors:  R M Sutherland
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

3.  Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo.

Authors:  J M Brown
Journal:  Radiat Res       Date:  1977-12       Impact factor: 2.841

4.  Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers.

Authors:  G E Adams; I R Flockhart; C E Smithen; I J Stratford; P Wardman; M E Watts
Journal:  Radiat Res       Date:  1976-07       Impact factor: 2.841

5.  Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole.

Authors:  I R Flockhart; P Large; D Troup; S L Malcolm; T R Marten
Journal:  Xenobiotica       Date:  1978-02       Impact factor: 1.908

6.  Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.

Authors:  R C Urtasun; P Band; J D Chapman; H R Rabin; A F Wilson; C G Fryer
Journal:  Radiology       Date:  1977-03       Impact factor: 11.105

7.  Effect of hyperthermia on cytotoxicity of the radiosensitizer Ro-07-0582 in a solid mouse tumour.

Authors:  K C George; D G Hirst; N J McNally
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

8.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

9.  Studies with bleomycin and misonidazole on aerated and hypoxic cells.

Authors:  L Roizin-Towle; E J Hall
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

10.  Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1977-02       Impact factor: 7.640

View more
  18 in total

1.  Potentiation of CCNU activity by misonidazole in metastases.

Authors:  D W Siemann; K L Alliet
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

2.  Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase.

Authors:  M R Horsman; D M Brown; D G Hirst; J M Brown
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

3.  Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

4.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

5.  Effect of the nitroimidazole Ro 03-8799 on the activity of chemotherapeutic agents against a murine tumour in vivo.

Authors:  P W Sheldon; P Gibson
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

6.  Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivo.

Authors:  C Grau; S M Bentzen; J Overgaard
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

7.  Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.

Authors:  J M Brown; D G Hirst
Journal:  Br J Cancer       Date:  1982-05       Impact factor: 7.640

8.  Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.

Authors:  M R Horsman; J W Evans; J M Brown
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

9.  Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.

Authors:  P Twentyman; P Workman
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

10.  Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo.

Authors:  D Murray; R E Meyn
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.